In short, the expression level of PD-1 was bound up with breast cancer malignancy, which could be used as a potential biomarker; PD-1 might manipulate the anti-tumor immune response by impacting not just T cells, and this might vary among different tumor types. The gene discussed is PDCD1; the disease is breast cancer.